


LY3509754

Cat. No.:	HY-139206		
CAS No.:	2452464-73-0		
Molecular Formula:	C ₂₄ H ₂₇ F ₅ N ₈ O ₄		
Molecular Weight:	586.51		
Target:	Interleukin Related		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (426.25 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	1.7050 mL	8.5250 mL	17.0500 mL
		5 mM	0.3410 mL	1.7050 mL	3.4100 mL
10 mM		0.1705 mL	0.8525 mL	1.7050 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (3.55 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	LY3509754 (IL-17A inhibitor 1) is a IL-17A inhibitor, with IC ₅₀ values of <9.45 nM and 9.3 nM in alphasisa assay and HT-29 cells [1].
IC₅₀ & Target	IL-17
In Vivo	LY3509754 (example 24) possesses high oral bioavailability (F=107%) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. COATES DAVID ANDREW, et al. IMIDAZO[1,2-B]PYRIDAZINE IL-17A INHIBITORS. Patent WO2020146194.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA